Company Overview and News

LongFin: A Reminder In The Dangers Of Indexing

2018-04-04 seekingalpha
As passive investing continues to grow, there will be more ways for ETF holders to get hurt.
Upvote Downvote

5 Best ETF Charts of Q4 Earnings

2018-03-06 zacks
The Q4 earnings season has reached its tail end with 97.1% of the S&P 500 index market capitalization that has reported so far up 14% on 8.5% revenue growth, with 77.2% beating EPS estimates and 76% coming ahead of top-line expectations. Earnings and revenue growth rates are much higher for the same group of companies than in the past few quarters. Additionally, earnings and revenue surprises are also tracking above historical levels.
Upvote Downvote

The Zacks Analyst Blog Highlights: First Trust NASDAQ, Guggenheim Solar, iShares U.S. Aerospace, Spirited Funds and iShares U.S. Consumer

2018-03-06 zacks
Chicago, IL – March 6, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include First Trust NASDAQ Global Auto Index Fund (CARZ - Free Report) , Guggenheim Solar ETF (TAN - Free Report) , iShares U.S. Aerospace & Defense ETF (ITA - Free Report) , Spirited Funds/ETFMG Whiskey & Spirits ETF (WSKY - Free Report) and iShares U.
Upvote Downvote

Trump Tariffs Put These Sector ETFs & Stocks in Focus

2018-03-05 zacks
Trump’s announcement that the United States will impose a 25% tariff on steel imports and a 10% tariff on aluminum imports has become the latest cause of concern for the U.S. economy and Wall Street. The tariffs are likely to result in an increase in raw material cost for manufacturers that use these metals.
Upvote Downvote

Alternative Energy ETFs to Gain From First Solar Q4 Results

2018-02-23 zacks
Leading U.S. solar-panel manufacturer, First Solar (FSLR - Free Report) reported fourth-quarter 2017 results after the closing bell yesterday. The company reported narrower-than-expected loss and raised its full-year outlook despite lagging revenue estimates. Loss per share was 25 cents, narrower than the Zacks Consensus Estimate of 32 cents. First Solar had posted earnings of $1.24 in the year-ago quarter.
Upvote Downvote

Trump Solar Tariff's Winners And Losers

2018-01-26 seekingalpha
President Trump's U.S. Trade Representative imposed new tariffs for a period of 4 years on imported solar cells and modules.
Upvote Downvote

The Best Healthcare REITs To Buy At A Bargain

2018-01-23 seekingalpha
In every article about healthcare, the constant refrain is about the aging baby boomers. While I agree with the enthusiasm, my opinion has tempered over time.
Upvote Downvote

Trump's Import Tariffs: ETF & Stocks in Focus

2018-01-23 zacks
As a part of its protectionist agenda, U.S.president Donald Trump levied tariffs on imported solar panels and washing machines. The government will now impose new duties of as much as 30% on foreign-made solar equipment, as reported by the U.S. Trade Representative’s office on Jan 22, 2018. The President also seeks to slap tariffs starting as high as 50% on imported washing machines, according to USTR.
Upvote Downvote

8 New ETFs of 2017 to Explode in 2018

2018-01-04 zacks
Over 270 ETFs were launched in 2017 and many are in the pipeline waiting for approval. But investors must be knowing that not all get to see the same success after months of trading. Some die an early death while some keep getting fuller with assets over time. Below we highlight a few new ETFs that may see smooth trading in 2018 and make a killing (read: 7 Successful New ETFs of 2017).
Upvote Downvote

4 Top ETF Areas of Q4

2017-12-26 zacks
The final quarter of 2017 is drawing to an end. The journey has been smooth so far, thanks to the Trump trade and tax reform talks. Also, the quarter is known for Santa Rally and holiday shopping season. And even though the Fed has enacted its final rate hike of the year earlier this month, the move was already baked in at the current level.
Upvote Downvote

Top Sector ETFs of 2017

2017-12-22 zacks
As we are approaching the end of 2017, it’s time to look back at the hot investing areas of 2017. This is especially true as this year has treated the broader market well. The S&P 500 has gained about 19%, the Nasdaq has crossed the 7000 mark and the Dow Jones hit several highs. However, some specific sectors shone even brighter in the galaxy of equities in 2017. Below we highlight those wining ones.
Upvote Downvote

Solar Stocks Surge As Canadian Solar CEO Aims to Go Private

2017-12-12 zacks
Several major solar energy stocks, including SolarEdge Technologies (SEDG - Free Report) and SunPower Corporation (SPWR - Free Report) , surged on Monday morning after Canadian Solar’s (CSIQ - Free Report) CEO announced his plan to take the company private.
Upvote Downvote

3 ETF Areas May Come Under Pressure on Tax Reform

2017-12-12 zacks
With the U.S. tax reform looking more realistic, the global investing world is rejoicing the expected move. However, all is not rosy for the investing landscape. There are certain areas that maybe troubled if the tax reform is passed with the current proposals. Below we highlight those areas (read: Senate Passes Tax Bill: 5 ETFs to Buy Now).
Upvote Downvote

SolarEdge: Don't Buy The Dip

2017-12-05 seekingalpha
SolarEdge posted impressive Q3 earnings and the stock soared upward before correcting downward this past week.
Upvote Downvote

What to Expect from Yingli Solar’s 3Q17 Earnings

2017-11-27 marketrealist
Yingli Solar (YGE) will announce its 3Q17 earnings results on December 6, 2017, before market hours. In this earning series, we’ll discuss analysts’ expectations for Yingli Solar’s upcoming 3Q17 earnings release. We’ll look at the factors that led analysts to come up with these expectations. We’ll also go through the company’s 2017 guidance and key metrics for investors.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

11h - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 18383Q739